Clinical Trials

While investors grow weary of AI promises, Yidu Tech is turning a profit by building the unglamorous data infrastructure that makes real innovation possible.

Valgen Medtech's dual EU approval for its heart valve device isn't just a clinical win; it's a tremor in the global medical technology landscape.

With its U.S. launch underway, Nyxoah is betting its innovative Genio system can unseat an industry giant. But can it chart a path to profitability?

A medical breakthrough in neurostimulation could dramatically increase the supply of lungs for transplant, tackling a critical shortage and saving lives.

With 40M more patients now covered, Kerecis's fish-skin technology is set for accelerated adoption, driven by powerful clinical data and payor confidence.

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Veristat isn't just hiring; it's assembling a brain trust to conquer biotech's toughest frontiers. Here's the story behind its strategic talent grab.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

With a $43M funding boost, Irish innovator CroíValve is expanding trials for its unique 'Adaptive Coaptation' device, aiming to transform treatment for millions.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.